169 related articles for article (PubMed ID: 31540136)
1. Liraglutide Inhibits Hepatitis C Virus Replication Through an AMP Activated Protein Kinase Dependent Mechanism.
Lee MY; Chen WC; Hsu WH; Chen SC; Lee JC
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31540136
[TBL] [Abstract][Full Text] [Related]
2. Endocannabinoid system activation contributes to glucose metabolism disorders of hepatocytes and promotes hepatitis C virus replication.
Sun LJ; Yu JW; Wan L; Zhang XY; Shi YG; Chen MY
Int J Infect Dis; 2014 Jun; 23():75-81. PubMed ID: 24704332
[TBL] [Abstract][Full Text] [Related]
3. Liraglutide, a GLP-1 receptor agonist, inhibits vascular smooth muscle cell proliferation by enhancing AMP-activated protein kinase and cell cycle regulation, and delays atherosclerosis in ApoE deficient mice.
Jojima T; Uchida K; Akimoto K; Tomotsune T; Yanagi K; Iijima T; Suzuki K; Kasai K; Aso Y
Atherosclerosis; 2017 Jun; 261():44-51. PubMed ID: 28445811
[TBL] [Abstract][Full Text] [Related]
4. Glucagon-like peptide-1 analogs activate AMP kinase leading to reversal of the Warburg metabolic switch in breast cancer cells.
Ligumsky H; Amir S; Arbel Rubinstein T; Guion K; Scherf T; Karasik A; Wolf I; Rubinek T
Med Oncol; 2024 May; 41(6):138. PubMed ID: 38705935
[TBL] [Abstract][Full Text] [Related]
5. The human glucagon-like peptide-1 analogue liraglutide regulates pancreatic beta-cell proliferation and apoptosis via an AMPK/mTOR/P70S6K signaling pathway.
Miao XY; Gu ZY; Liu P; Hu Y; Li L; Gong YP; Shu H; Liu Y; Li CL
Peptides; 2013 Jan; 39():71-9. PubMed ID: 23116613
[TBL] [Abstract][Full Text] [Related]
6. The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanism.
Andreozzi F; Raciti GA; Nigro C; Mannino GC; Procopio T; Davalli AM; Beguinot F; Sesti G; Miele C; Folli F
J Transl Med; 2016 Jul; 14(1):229. PubMed ID: 27473212
[TBL] [Abstract][Full Text] [Related]
7. Synergistic effects of metformin with liraglutide against endothelial dysfunction through GLP-1 receptor and PKA signalling pathway.
Ke J; Liu Y; Yang J; Lu R; Tian Q; Hou W; Wang G; Wei R; Hong T
Sci Rep; 2017 Feb; 7():41085. PubMed ID: 28145471
[TBL] [Abstract][Full Text] [Related]
8. DDX60L Is an Interferon-Stimulated Gene Product Restricting Hepatitis C Virus Replication in Cell Culture.
Grünvogel O; Esser-Nobis K; Reustle A; Schult P; Müller B; Metz P; Trippler M; Windisch MP; Frese M; Binder M; Fackler O; Bartenschlager R; Ruggieri A; Lohmann V
J Virol; 2015 Oct; 89(20):10548-68. PubMed ID: 26269178
[TBL] [Abstract][Full Text] [Related]
9. GLP-1 receptor agonist impairs keratinocytes inflammatory signals by activating AMPK.
Yang J; Wang Z; Zhang X
Exp Mol Pathol; 2019 Apr; 107():124-128. PubMed ID: 30776356
[TBL] [Abstract][Full Text] [Related]
10. 2-octynoic acid inhibits hepatitis C virus infection through activation of AMP-activated protein kinase.
Yang D; Xue B; Wang X; Yu X; Liu N; Gao Y; Liu C; Zhu H
PLoS One; 2013; 8(5):e64932. PubMed ID: 23741428
[TBL] [Abstract][Full Text] [Related]
11. Double-stranded RNA-activated protein kinase inhibits hepatitis C virus replication but may be not essential in interferon treatment.
Chang JH; Kato N; Muroyama R; Taniguchi H; Guleng B; Dharel N; Shao RX; Tateishi K; Jazag A; Kawabe T; Omata M
Liver Int; 2010 Feb; 30(2):311-8. PubMed ID: 19840259
[TBL] [Abstract][Full Text] [Related]
12. GLP-1 receptor agonist liraglutide protects cardiomyocytes from IL-1β-induced metabolic disturbance and mitochondrial dysfunction.
Zhang L; Tian J; Diao S; Zhang G; Xiao M; Chang D
Chem Biol Interact; 2020 Dec; 332():109252. PubMed ID: 32898504
[TBL] [Abstract][Full Text] [Related]
13. Glucagon-like peptide-1 alleviates diabetic kidney disease through activation of autophagy by regulating AMP-activated protein kinase-mammalian target of rapamycin pathway.
Yang S; Lin C; Zhuo X; Wang J; Rao S; Xu W; Cheng Y; Yang L
Am J Physiol Endocrinol Metab; 2020 Dec; 319(6):E1019-E1030. PubMed ID: 32985256
[TBL] [Abstract][Full Text] [Related]
14. Endocannabinoid CB1 antagonists inhibit hepatitis C virus production, providing a novel class of antiviral host-targeting agents.
Shahidi M; Tay ESE; Read SA; Ramezani-Moghadam M; Chayama K; George J; Douglas MW
J Gen Virol; 2014 Nov; 95(Pt 11):2468-2479. PubMed ID: 25053565
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of hepatitis C virus replication through adenosine monophosphate-activated protein kinase-dependent and -independent pathways.
Nakashima K; Takeuchi K; Chihara K; Hotta H; Sada K
Microbiol Immunol; 2011 Nov; 55(11):774-82. PubMed ID: 21895746
[TBL] [Abstract][Full Text] [Related]
16. Liraglutide enhances glucose transporter 4 translocation via regulation of AMP-activated protein kinase signaling pathways in mouse skeletal muscle cells.
Li Z; Ni CL; Yao Z; Chen LM; Niu WY
Metabolism; 2014 Aug; 63(8):1022-30. PubMed ID: 24972503
[TBL] [Abstract][Full Text] [Related]
17. Acetylsalicylic acid inhibits hepatitis C virus RNA and protein expression through cyclooxygenase 2 signaling pathways.
Trujillo-Murillo K; Rincón-Sánchez AR; Martínez-Rodríguez H; Bosques-Padilla F; Ramos-Jiménez J; Barrera-Saldaña HA; Rojkind M; Rivas-Estilla AM
Hepatology; 2008 May; 47(5):1462-72. PubMed ID: 18393288
[TBL] [Abstract][Full Text] [Related]
18. Liraglutide, a glucagon-like peptide-1 receptor agonist, facilitates osteogenic proliferation and differentiation in MC3T3-E1 cells through phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT), extracellular signal-related kinase (ERK)1/2, and cAMP/protein kinase A (PKA) signaling pathways involving β-catenin.
Wu X; Li S; Xue P; Li Y
Exp Cell Res; 2017 Nov; 360(2):281-291. PubMed ID: 28919123
[TBL] [Abstract][Full Text] [Related]
19. [Inhibition of hepatitis C virus replication by mycophenolic acid in hepatocytes].
Chen H; Ye L; Su JM; Li Y; Zeng JR; Huo WZ
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2013 Feb; 27(1):35-8. PubMed ID: 23855126
[TBL] [Abstract][Full Text] [Related]
20. Effect of ethanol on innate antiviral pathways and HCV replication in human liver cells.
Plumlee CR; Lazaro CA; Fausto N; Polyak SJ
Virol J; 2005 Dec; 2():89. PubMed ID: 16324217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
